Management of Bladder Pain Syndrome
Definition and Diagnostic Criteria
Bladder pain syndrome (BPS) is a diagnosis of exclusion — there is no single definitive test. Two working definitions are in use:
- European Society (ESSIC, 2008): pelvic pain, pressure or discomfort perceived to be related to the bladder, lasting at least 6 months, and accompanied by at least one other urinary symptom (e.g. persistent urge to void or frequency), in the absence of other identifiable causes.
- American Urological Association (preferred by the guideline): an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the bladder, associated with lower urinary tract symptoms of more than 6 weeks' duration, in the absence of infection or other identifiable causes.
Symptom-severity questionnaires (e.g. the Interstitial Cystitis Symptom and Problem Indices, visual analogue/numeric pain rating scales) are used to characterise and track severity rather than to diagnose.
Investigation
- Urinalysis and urine culture to exclude urinary tract infection — a prerequisite before labelling symptoms as BPS.
- Cystoscopy with hydrodistension under anaesthesia is both diagnostic and potentially therapeutic: it can identify Hunner's lesions (a distinct, more treatable ulcerative phenotype), though cystoscopic changes can also occur in asymptomatic women, so findings must be interpreted alongside symptoms.
- Urodynamic studies may be used as part of the wider work-up to exclude other causes of the symptom complex.
- Bladder diaries and pain-mapping support diagnosis and monitor response to treatment.
Management Ladder
Treatment is stepwise, moving from conservative measures to increasingly invasive options only as required, since evidence quality diminishes and morbidity increases further up the ladder.
First-line — conservative: patient education, self-management, dietary modification (avoiding recognised bladder irritants such as caffeine, alcohol, and acidic foods), fluid and stress management, and myofascial physical therapy, which has trial evidence of benefit particularly where pelvic floor tenderness is present.
Second-line — oral and intravesical pharmacotherapy:
- Oral: amitriptyline (tricyclic antidepressant, low-dose initiation), cimetidine, hydroxyzine, and pentosan polysulfate sodium, used alone or in combination.
- Intravesical instillation: dimethyl sulfoxide (DMSO), heparin, alkalinised lidocaine, and combined hyaluronic acid/chondroitin sulfate.
Third-line: repeat cystoscopy with hydrodistension, with fulguration or laser treatment of Hunner's lesions where present, and intradetrusor/suburothelial botulinum toxin A injection for refractory disease (sometimes combined with hydrodistension).
Fourth-line — neuromodulation: sacral neuromodulation (S3 nerve stimulation) and posterior tibial nerve stimulation (PTNS) for persistent urgency-frequency symptoms unresponsive to earlier steps.
Fifth-line: oral ciclosporin A (low dose) reserved for severe, refractory Hunner's-lesion disease under specialist supervision because of its toxicity profile.
Sixth-line — major surgery (last resort): augmentation (ileo)cystoplasty with supratrigonal cystectomy, or urinary diversion (with or without cystectomy), for severe, treatment-resistant ulcerative disease once all other options are exhausted.
Opioid analgesia should follow an "Opioids Aware" stewardship approach rather than being used as routine long-term therapy.
High-Yield Exam Points
- BPS is a diagnosis of exclusion — always rule out UTI (urinalysis and culture) first.
- Two accepted definitions exist; know that both require absence of infection/other cause plus chronic urinary symptoms with bladder pain, differing mainly in minimum duration (6 weeks AUA vs 6 months ESSIC).
- Hunner's lesions, seen at cystoscopy with hydrodistension, define a distinct ulcerative phenotype that responds better to fulguration/laser and intralesional treatment than non-ulcerative BPS.
- Management is a stepwise ladder: conservative → oral/intravesical therapy → cystoscopic/botulinum toxin → neuromodulation → ciclosporin A → major reconstructive surgery (cystoplasty/diversion) as last resort.
- Amitriptyline, cimetidine and pentosan polysulfate are the key oral agents to recognise; DMSO, heparin and hyaluronic acid/chondroitin sulfate are the key intravesical agents.
Source: RCOG Green-top Guideline No. 70 (RCOG/BSUG joint guideline) (First published November 2016; reviewed by the Guidelines Committee May 2023 (confirmed current — an update is in development, no revised edition published as of this writing))
Read the original on rcog.org.uk
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).